Abstract
The nature and symptoms of Alzheimer's disease present unique issues and problems related to the design and analysis of clinical trials for assessing the efficacy of potential therapies. Based on the author's involvement with two multicenter studies in Alzheimer's patients, issues related to the design and analysis of such trials are discussed. Due to the progressive nature of the disease and the potential for carryover and withdrawal effects, crossover and enriched population designs are not recommended. Instead, parallel group comparisons are preferable. Since Alzheimer's disease has both cognitive and behavioral symptoms, both an objective cognitive test and a global assessment are recommended primary outcome variables. Other important design issues are specification of efficacy criteria, length of the double-blind treatment period, dose escalation, and follow-up of dropouts. With respect to statistical analysis, it is important to include all randomized patients in the analysis and to make every possi...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
